about
Targeting of erbB3 receptor to overcome resistance in cancer treatmentCombination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaA novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsEmerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor ReceptorFunction and mode of action of cytohesins in the epidermal growth factor pathway in colorectal cancer cellsPreclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules.Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.Advances in Targeting HER3 as an Anticancer TherapyA Conjugate of an Anti-Epidermal Growth Factor Receptor (EGFR) VHH and a Cell-Penetrating Peptide Drives Receptor Internalization and Blocks EGFR Activation.An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis.ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression.EGFR signaling patterns are regulated by its different ligands.Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
P2860
Q26864668-99029BE6-DBA5-438D-93FA-9AE7EACFCBEBQ33875560-DA6807C8-6137-4E43-91DB-2B35603B8EAAQ35199371-7ABCD6AD-2DA8-4C63-8370-92FE55CCABA5Q35201923-93D946A4-27B4-483C-9396-5D562E102EBBQ36111593-376A37A1-71D0-4BAE-848A-43796E46E789Q36117785-236A17D2-83E9-40FF-9B5C-5A7443910052Q36388482-2A2097F6-660D-4C95-A276-46607F9E44A2Q36611657-B53602F2-F1D6-4BAF-A80C-13B3E10D13D6Q37109776-4BF26DED-FE03-4D81-AA76-DA2AE5240C6CQ38749027-BD43B190-ACDE-4BAF-8E2A-57DF7A298B9AQ38757863-BA76A9A2-30B5-47F6-9D0D-A1E07D004737Q38760738-F2BF4142-A320-4662-B72C-12DED79AFF46Q38867798-A0ABE167-B785-4051-96F6-C40F06BC32FCQ38869420-2CEE6F29-7309-4F49-AD27-9E7FBD296ECCQ38929801-E40AC59D-F642-4EC2-B69D-BE47555A1A2EQ39045763-35D0A1DA-8C9D-4096-A3F8-BDD09B6F950BQ41621146-2278FA2F-1058-4964-AF70-10A6FF756E87Q48218073-7FB4FF02-916B-4A77-A797-07080D6DB446Q53222808-69DBC543-CAC3-44C9-B278-FBEC0C6BEE3EQ54276976-775EA590-69C9-40C3-876B-10AC7EDD7C12Q54301389-2C8524F5-7301-43FB-8D8B-26F1EC9F641FQ55060477-F367A653-52B5-42E3-A0E2-2FB3945CCA62Q55070997-6A2E8A7A-4AE0-4A1D-AD2A-8EBCCB7D67BBQ57818008-F4471190-1F4C-4F6A-97E9-CF66F03EA4A8
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Resistance to EGFR-targeted therapy: a family affair.
@en
Resistance to EGFR-targeted therapy: a family affair.
@nl
type
label
Resistance to EGFR-targeted therapy: a family affair.
@en
Resistance to EGFR-targeted therapy: a family affair.
@nl
prefLabel
Resistance to EGFR-targeted therapy: a family affair.
@en
Resistance to EGFR-targeted therapy: a family affair.
@nl
P2860
P1433
P1476
Resistance to EGFR-targeted therapy: a family affair.
@en
P2093
Gregory Vlacich
Robert J Coffey
P2860
P304
P356
10.1016/J.CCR.2011.10.006
P577
2011-10-01T00:00:00Z